Back to Investors
Investment Case
A diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology Manufacturers, Uniphar represents a strong combination of scale, growth and profitability.
In 2025, the Group generated revenue of €3.1bn, gross profit of €458m and EBITDA of €131m. With a workforce of 3,589, the Group is active in Ireland, Europe, USA, APAC and MENA.
Full Year 2025 Results
FY 2025 Key Stats
€130.9m
EBITDA
8.9%
Organic GP Growth YoY
16.3%
ROCE
24.8c
Adjusted EPS
Group Highlights
€457.7m
2025 GP
Partnering with all of the top 10 pharma companies
and 7 of the top 10 medical device companies
